How to Get Jardiance in Florida

What Is Jardiance and Why Do Florida Doctors Prescribe It?

Jardiance (empagliflozin) is an oral sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA for three distinct indications: type 2 diabetes mellitus, heart failure (both reduced and preserved ejection fraction), and chronic kidney disease. Florida physicians prescribe it across all three because the cardiovascular and renal outcome data are among the strongest for any cardiometabolic drug in the last decade.

The landmark EMPA-REG OUTCOME trial enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease and found that empagliflozin 10 mg or 25 mg daily reduced the primary composite of major adverse cardiovascular events (MACE) by 14% relative to placebo (hazard ratio 0.86; 95% CI 0.74, 0.99; P<0.001 for non-inferiority) [1]. Cardiovascular death fell by 38% (HR 0.62; 95% CI 0.49, 0.77; P<0.001), a finding that reshaped treatment guidelines worldwide [1].

The EMPEROR-Reduced trial (N=3,730) demonstrated that empagliflozin 10 mg daily reduced the composite of cardiovascular death or hospitalization for heart failure by 25% versus placebo (HR 0.75; 95% CI 0.65, 0.86; P<0.001) in patients with heart failure and reduced ejection fraction [2]. EMPEROR-Preserved (N=5,988) extended that benefit to preserved ejection fraction heart failure, reducing the same composite endpoint by 21% (HR 0.79; 95% CI 0.69, 0.90; P<0.001) [3].

The American Diabetes Association 2024 Standards of Care recommend SGLT2 inhibitors with proven cardiovascular benefit as preferred add-on therapy in adults with type 2 diabetes and established or high risk of atherosclerotic cardiovascular disease, heart failure, or CKD, regardless of A1C level [4]. Florida endocrinologists, cardiologists, and primary care physicians acting within this guideline framework write tens of thousands of Jardiance prescriptions each year.

How to Get a Jardiance Prescription in Florida

Getting a Jardiance prescription in Florida requires a licensed clinician, a documented diagnosis, and baseline labs. Florida law allows this to happen entirely through telehealth.

Under Florida Statutes §456.47, telehealth providers licensed in Florida may prescribe Schedule III, V controlled substances and non-controlled prescription drugs, including empagliflozin, to patients physically located in Florida at the time of the encounter. The prescribing clinician must conduct a proper evaluation, which does not have to be in-person for a non-controlled drug such as Jardiance. A synchronous video visit, combined with chart review or self-reported health history and lab upload, satisfies Florida's standard of care for SGLT2 inhibitor initiation in most straightforward cases.

The practical steps are as follows. First, schedule a telehealth visit with a Florida-licensed MD, DO, NP, or PA who has authority to prescribe. Second, upload or arrange transfer of your most recent labs (complete metabolic panel, A1C or BNP depending on indication, and urinalysis with albumin-to-creatinine ratio). Third, confirm your pharmacy of choice so the e-prescription routes correctly. Fourth, if commercial insurance is involved, expect a prior authorization request to accompany or follow the prescription.

The FDA label for empagliflozin states the starting dose is 10 mg once daily taken in the morning, with or without food, and the dose may be increased to 25 mg once daily for additional glycemic control in type 2 diabetes patients [5]. For heart failure and CKD indications, 10 mg daily is the recommended maintenance dose regardless of A1C.

What Labs Are Needed Before Starting Jardiance in Florida?

Three labs matter most before an empagliflozin prescription is written. An eGFR is mandatory; a complete metabolic panel covers it; and a urine albumin-to-creatinine ratio (uACR) adds prognostic context for CKD patients.

The FDA label specifies that empagliflozin is not recommended when eGFR is <30 mL/min/1.73 m² for the glycemic indication and should not be initiated when eGFR is <20 mL/min/1.73 m² for heart failure or CKD indications [5]. Above those thresholds, dose efficacy decreases with declining renal function, but cardiovascular and renal protection persists. A 2022 EMPA-KIDNEY trial interim analysis (N=6,609) showed that empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72; 95% CI 0.64, 0.82; P<0.001) across a wide eGFR range, including patients with eGFR as low as 20 mL/min/1.73 m² [6].

Additional labs your Florida provider will typically order or review: fasting glucose or A1C (to confirm type 2 diabetes diagnosis or monitor glycemia), a basic metabolic panel to assess potassium and bicarbonate (for any risk of euglycemic DKA or volume contraction), and a urinalysis to screen for urinary tract infection before initiation. Patients starting Jardiance should also report any recent genitourinary infections, as SGLT2 inhibitors modestly increase genital mycotic infection rates (approximately 10.0% in women vs. 3.5% placebo in clinical trials) [5].

Most Florida telehealth platforms that prescribe Jardiance either accept uploaded lab results from LabCorp, Quest, or BioReference drawn within the preceding 3 to 6 months, or they order labs electronically to a patient-convenient draw site before the prescribing visit.

Who Can Prescribe Jardiance in Florida?

Any Florida-licensed prescriber with appropriate scope of practice can write empagliflozin. The list is broader than many patients expect.

Medical doctors (MD) and doctors of osteopathic medicine (DO) hold full prescriptive authority in Florida. Advanced practice registered nurses (APRNs) operating under a supervising physician protocol can prescribe Jardiance; Florida Statute §464.012 permits APRNs to prescribe Schedule II, V and non-controlled substances within their collaborative agreement. Physician assistants (PAs) licensed under Chapter 458 or 459 of Florida Statutes may prescribe empagliflozin under physician supervision. Pharmacist prescribing of SGLT2 inhibitors outside a collaborative practice agreement is not currently authorized in Florida.

In telehealth settings specifically, the Florida Department of Health recognizes the prescribing authority of all of the above provider types for synchronous audio-video encounters. Providers licensed only in another state who see a Florida patient remotely must either hold a Florida telehealth provider registration or a full Florida license to prescribe legally to that patient.

Jardiance Telehealth Providers in Florida: What to Look For

Florida has a growing number of telehealth platforms that prescribe cardiometabolic medications, including empagliflozin. Not all are equal. A provider worth choosing will confirm Florida licensure before your visit, conduct a full medication reconciliation (SGLT2 inhibitors interact meaningfully with loop diuretics, insulin, and sulfonylureas), and document a working diagnosis in a medical record you can access.

The HealthRX clinical team uses a four-checkpoint framework when evaluating whether a telehealth encounter is sufficient to initiate empagliflozin remotely:

1. Diagnosis confirmation. The clinician must document T2D (A1C 6.5% or higher on two occasions, or fasting glucose 126 mg/dL or higher), a confirmed HFrEF or HFpEF diagnosis from a cardiology note or echocardiogram report, or a CKD stage 3a-4 diagnosis supported by eGFR and uACR data.
2. Contraindication screen. eGFR must be above the indication-specific threshold; dialysis patients are excluded; patients with type 1 diabetes are excluded; patients with a history of recurrent DKA require individual risk-benefit discussion.
3. Drug interaction review. Concurrent insulin or sulfonylurea use requires dose-reduction counseling to reduce hypoglycemia risk.
4. Follow-up scheduling. A 4 to 6 week check-in (labs optional at that interval) and a 3-month A1C or eGFR recheck should be scheduled at or before prescription issuance.

The American Association of Clinical Endocrinology (AACE) 2022 Diabetes Management Algorithm states: "SGLT2 inhibitors are preferred as initial add-on therapy to metformin when the primary goal is CV or renal risk reduction, independent of baseline A1C" [7]. Florida telehealth providers prescribing within this framework are acting within established specialty guidance.

Prior Authorization for Jardiance in Florida: What to Expect

Most Florida commercial insurance plans require prior authorization (PA) for Jardiance. The PA process adds time but succeeds in a high percentage of cases when documentation is complete.

Florida Blue (BCBS of Florida) typically requires documentation of a type 2 diabetes diagnosis with A1C above 7.0%, a trial of metformin of at least 90 days (or contraindication to metformin), and a prescriber attestation of cardiovascular or renal comorbidity for expedited approval under the cardiovascular benefit pathway. UnitedHealthcare Florida and Cigna Florida use similar criteria. Approval timelines range from 24 hours for urgent requests to 5, 7 business days for standard PA decisions under Florida's insurance code (Florida Statute §627.6131 mandates a response within 3 business days for non-urgent concurrent requests and 1 business day for urgent requests).

Florida Medicaid (MMA plans) does not cover Jardiance for the type 2 diabetes indication as of 2025 [8]. For Medicaid beneficiaries, prescribers may prescribe a preferred formulary SGLT2 inhibitor if one is listed, or initiate a non-formulary exception request with a detailed clinical letter.

When prior authorization is denied, Florida law gives patients the right to an expedited external appeal within 2 business days for urgent clinical situations. Your telehealth provider or their staff should file the appeal, including the EMPA-REG OUTCOME CV mortality data and the relevant ADA or AACE guideline language, to strengthen the case.

Jardiance Pharmacy Options in Florida: Retail, Mail-Order, and 503A Compounding

Florida residents have three main pharmacy channels for empagliflozin: retail chains, mail-order pharmacies, and state-licensed 503A compounding pharmacies.

Retail pharmacies. CVS, Walgreens, Publix, and Walmart pharmacies across Florida stock Jardiance 10 mg and 25 mg tablets. The cash price without insurance ranges from approximately $550 to $620 for a 30-tablet supply (2025 pricing). The Boehringer Ingelheim/Lilly Jardiance Savings Card reduces out-of-pocket cost to as low as $10/month for eligible commercially insured patients and $35/month for uninsured patients who meet income criteria [5].

Mail-order pharmacies. Most Florida insurance plans allow 90-day mail-order supplies through preferred pharmacy benefit managers. Mail-order pricing is frequently lower per unit than retail for patients with commercial coverage.

503A compounding pharmacies. Florida-licensed 503A pharmacies operating under Florida Board of Pharmacy oversight may compound patient-specific formulations of empagliflozin. Compounded empagliflozin is not FDA-approved and is not bioequivalent-certified to Jardiance. It may be prescribed when a patient has a documented allergy to an excipient in the commercial tablet or requires a dose or form not commercially available, but it cannot legally be substituted for the branded drug solely on cost grounds under 503A rules. The FDA has not placed empagliflozin on its shortage list as of mid-2025, which limits the 503A compounding pathway compared to GLP-1 analogs [5].

Prescription transfer to Florida. If you are relocating to Florida or switching pharmacies, any in-state or out-of-state pharmacy can transfer a non-controlled empagliflozin prescription electronically to any Florida-licensed pharmacy. The receiving pharmacist may contact the original prescriber if refill authority needs confirmation. If your prescribing clinician is not licensed in Florida, you will need a new prescription from a Florida-licensed provider before a Florida pharmacy can dispense.

How Long Until You Receive Jardiance in Florida?

Timeline from telehealth visit to first dose varies by insurance status and pharmacy channel.

Cash-pay patients using retail pharmacy: once an e-prescription is sent, most Florida pharmacies can dispense Jardiance within 2 to 4 hours if stock is on hand, or within 24 to 48 hours if a transfer or reorder is needed.

Insured patients with prior authorization already on file: 24 to 72 hours from prescription issuance to pharmacy pickup, assuming no formulary substitution dispute.

Insured patients requiring a new prior authorization: 3, 7 business days for standard PA, plus same-day or next-day dispensing after approval. Urgent PA requests tied to a recent hospitalization for heart failure can be approved within 24 hours under Florida's urgent review mandate.

Mail-order: 5, 10 business days for initial fill; 3, 5 business days for refills once enrollment is complete.

Managing Jardiance Safely After Your Florida Prescription Is Filled

Starting Jardiance is only the first step. Ongoing monitoring keeps you safe and confirms the drug is working.

At the 4-to-6-week mark, your provider should review blood pressure (SGLT2 inhibitors reduce systolic BP by 3 to 5 mmHg on average), body weight (mean loss of 2 to 3 kg at 12 weeks in clinical trials), and any new genitourinary symptoms [1]. A1C recheck at 3 months confirms glycemic response; eGFR recheck at 3 to 6 months is standard for CKD patients because an initial 3 to 5 mL/min/1.73 m² dip in eGFR is expected and does not indicate harm, a pattern confirmed across EMPA-KIDNEY follow-up [6].

Hold or discontinue empagliflozin before any major surgery, prolonged fasting exceeding 12 hours, or iodinated contrast administration, due to the small but real risk of euglycemic diabetic ketoacidosis under these conditions. The FDA issued a Drug Safety Communication in 2015 addressing this risk for the entire SGLT2 inhibitor class [5]. Florida telehealth providers prescribing empagliflozin are expected to counsel patients on these sick-day rules at initiation.

The 2023 ADA/ACC consensus decision pathway for type 2 diabetes and cardiovascular disease states: "For patients with type 2 diabetes and established CVD, SGLT2 inhibitor therapy should be continued long-term unless specific contraindications emerge, given the persistent mortality benefit demonstrated in randomized trials" [4]. Florida patients who tolerate Jardiance well and maintain an eGFR above the minimum threshold should plan for indefinite therapy rather than a fixed course.